Research
FORUM TRANSCRIPT

CRISPR-based Diagnostic Technology – Q1 2022 Update & Market Overview

  • Private Equity
  • Healthcare
  • Global
PREMIUM

Specialist

Former scientist at Synthetic Genomics Inc

Agenda

  • Key CRISPR technology trends and developments, focusing on CRISPR-based diagnostics and CRISPR Cas proteins 12, 13 and 14
  • CRISPR diagnostics competitive landscape and company dynamics, highlighting Mammoth Biosciences, Synthetic Genomics, Synthego, Caribou Biosciences (NASDAQ: CRBU) and Thermo Fisher Scientific (NYSE: TMO)
  • CRISPR-based diagnostics development, including set-up, process and differentiation vs NGS (next-generation sequencing), PCR (polymerase chain reaction) and LAMP (loop-mediated isothermal amplification)
  • CRISPR outlook – technology and commercialisation trends and increase uptake dependent on cost and ease of use

Questions

Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 25,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited